References

vtio

Вестник трансплантологии и искусственных органов

Russian Journal of Transplantology and Artificial Organs

1995-1191

Academician V.I.Shumakov National Medical Research Center of Transplantology and Artificial Organs", Ministry of Health of the Russian Federation

10.15825/1995-1191-2016-2-163-170

vtio-651

Research Article

Обзор литературы

Literature Reviews

ФАРМАКОЭКОНОМИЧЕСКОЕ ОБОСНОВАНИЕ ИСПОЛЬЗОВАНИЯ БЕЗИНТЕРФЕРОНОВЫХ ТЕРАПЕВТИЧЕСКИХ СХЕМ ПРИ ХРОНИЧЕСКОМ ГЕПАТИТЕ С ПОСЛЕ ТРАНСПЛАНТАЦИИ ПЕЧЕНИ

PHARMACOECONOMIC ASSESSMENT OF USING INTERFERON-FREE REGIMENS FOR CHRONIC HEPATITIS C AFTER LIVER TRANSPLANTATION

Сухорук

А. А.

Sukhoruk

A. A.

Для корреспонденции: Сухорук Анастасия Александровна. Адрес: 194100, Санкт-Петербург, ул. Литовская, д. 2. Тел. (812) 717-28-68. E-mail: infection-gpmu@mail.ru.

For correspondence: Sukhoruk Anastasiia Alexandrovna. Address: 2, Litovskaya st.,Saint Petersburg, 194100,Russian Federation. Tel. (812) 717-28-68. E-mail: infection-gpmu@mail.ru.

infection-gpmu@mail.ru

Эсауленко

Е. В.

Esaulenko

E. V.

infection-gpmu@mail.ru

Санкт-Петербургский государственный педиатрический медицинский университет, Санкт-ПетербургРоссияSaint Petersburg State Pediatric Medical University, Saint PetersburgRussian Federation

2016

26062016

182163170

2016

Сухорук А.А., Эсауленко Е.В.

Sukhoruk A.A., Esaulenko E.V.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://journal.transpl.ru/vtio/article/view/651

В статье проведен анализ существующих схем комбинированной противовирусной терапии хронического гепатита С после трансплантации печени. Проведение противовирусной терапии с использованием пролонгированных интерферонов и рибавирина низкоэффективно и высокозатратно. Доказано клиническое и экономическое преимущество безинтерферонового режима лечения пациентов, инфицированных вирусом гепатита С 1-го генотипа, с использованием дасабувира, паритапревира, бустированного ритонавиром, омбитасвира (Викейра Пак) и рибавирина. Регистрация и внедрение в клиническую практику новых препаратов прямого противовирусного действия позволит существенно расширить арсенал средств для лечения возвратной HCV-инфекции, в том числе у пациентов, инфицированным вирусом гепатита С 2-го и 3-го генотипа.

This article contains analysis of current combination treatment regimens for chronic hepatitis C after liver transplantation. Antiviral therapy with long-acting interferons and ribavirin is of low efficiency and high costs. The clinical and economic benefits of interferon-free treatment regimen for patients infected with genotype 1 HCV using dasabuvir, paritaprevir boosted with ritonavir, ombitasvir (Viekira Pak) and ribavirin have been shown. Registration and introduction into clinical practice of new direct-acting antiviral drugs will significantly expand the arsenal of tools for the treatment of recurrent HCV infections, in particular in patients infected with hepatitis C virus genotypes 2 and 3.

хронический гепатит Странсплантация печенибезинтерфероновый режиманализ затрат

chronic hepatitis Cliver transplantationinterferon-free regimencost-analysis

References1

Гранов АМ, Гранов ДА, Жеребцов ФК, Герасимова ОА, Боровик ВВ, Осовских ВВ и др. Трансплантация печени в РНЦРХТ. Опыт 100 операций. Вестник трансплантологии и искусственных органов. 2012; 14 (4): 11–16. DOI:10.15825/1995-1191-2012-4-11-16. Granov AM, Granov DA, Zherebtsov FK, Gerasimova OA, Borovik VV, Osovskikh VV et al. Liver transplantation. A single center experience of 100 cases. Russian Journal of Transplantology and Artificial Organs. 2012; 14 (4): 11–16. DOI: 10.15825/1995-1191-2012-4-11-16 [In Russ, English abstract].

Герасимова ОА, Гранов ДА, Жеребцов ФК. Сравнительная оценка результатов трансплантации печени больным с циррозом вирусной этиологии и аутоиммунными заболеваниями печени. Данные одного центра. Вестник трансплантологии и искусственных органов. 2012; 14 (1): 36–40. DOI: 10.15825/19951191-2012-1-36-40. Gerasimova OA, Granov DA, Zherebtsov FK. Comparative results of liver transplantation in patients with viral cirrhosis and autoimmune liver diseases at a single center. Russian Journal of Transplantology and Artificial Organs. 2012; 14 (1): 36–40. DOI: 10.15825/1995-1191-2012-1-36-40 [In Russ, English abstract].

Firpi RJ, Clark V, Soldevila-Pico C et al. The natural history of hepatitis C cirrhosis after liver transplantation. Liver Transplantation. 2009; 15: 1063–1071.

Эсауленко ЕВ, Сухорук АА, Герасимова ОА, Жеребцов ФК. Естественное течение хронического гепатита С после трансплантации печени. Инфекционные болезни. 2014; 12 (1): 22–27. Esaulenko EV, Sukhoruk AA, Gerasimova OA, Zherebcov FK. Estestvennoe techenie hronicheskogo gepatita C posle transplantacii pecheni. Infekcionnye bolezni. 2014; 12 (1): 22–27. [In Russ, English abstract].

Козлова АВ, Чжао АВ. Особенности течения возвратной HCV-инфекции у больных после трансплантации печени по поводу цирроза HCV-этиологии. Клинические перспективы гастроэнтерологии, гепатологии. 2011; 6: 11–16. Kozlova AV, Chzhao AV. Osobennosti techenija vozvratnoj HCV-infekcii u bol’nyh posle transplantacii pecheni po povodu cirroza HCVjetiologii. Klinicheskie perspektivy gastrojenterologii, gepatologii. 2011; 6: 11–16. [In Russ, English abstract].

Яковлев АА, Эсауленко ЕВ, Погромская МН, Федуняк ИП, Мусатов ВБ. Рациональная маршрутизация пациентов с хроническими вирусными гепатитами. Клинические перспективы гастроэнтерологии, гепатологии. 2015; 1: 3–8. Jakovlev AA, Еsaulenko EV, Pogromskaja MN, Fedunjak IP, Musatov VB. Racional’naja marshrutizacija pacientov s hronicheskimi virusnymi gepatitami. Klinicheskie perspektivy gastrojenterologii, gepatologii. 2015; 1: 3–8. [In Russ].

Рекомендации по диагностике и лечению взрослых больных гепатитом С. Под ред. В.Т. Ивашкина, Н.Д. Ющука, М.В. Маевской. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2013; 23 (2): С. 41–70. Rekomendacii po diagnostike i lecheniju vzroslyh bol’nyh gepatitom C. Pod red. V.T. Ivashkina, N.D. Jushhuka, M.V. Maevskoj. Rossijskij zhurnal gastrojenterologii, gepatologii, koloproktologii. 2013; 23 (2): S. 41–70. [In Russ].

EASL Recommendations on Treatment of Hepatitis C 2015. Journal of Hepatology. 2015; 63: 199–236.

Hepatitis C Guidance: AASLD-IDSA Recommendations for Testing, Managing, and Treating Adults Infected With Hepatitis C Virus. Hepatology. 2015; 62 (3): 932–954.

Hashemi N, Araya V, Tufail K, Thummalakunta L, Feyssa E, Azhar A et al. An extended treatment protocol with pegylated interferon and ribavirin for hepatitis C recurrence after liver transplantation. World J Hepatol. 2011; 3 (7): 198–204.

Babatin M, Schindel L, Burak KW. Pegylated-interferon alpha 2b and ribavirin for recurrent hepatitis C after liver transplantation: from a Canadian experience to recommendations for therapy. Can J Gastroenterol. 2005; 19: 359–365.

Biselli M, Andreone P, Gramenzi A, Lorenzini S, Loggi E,Bonvicini F et al. Pegylated interferon plus ribavirin for recurrent hepatitis C infection after liver transplantation in naive and nonresponder patients on a stable immunosuppressive regimen. Dig Liver Diseases. 2006; 38: 27–32.

Berenguer M, Palau A, Fernandez A, Benlloch S, Aguilera V, Prieto M et al. Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. Liver Transplant. 2006; 12: 1067–1076.

Oton E, Barcena R, Moreno-Planas JM, CuervasMons V, Moreno-Zamora A, Barrios C et al. Hepatitis C recurrence after liver transplantation: viral and histologic response to full-dose peg-interferon and ribavirin. Am J Transplant. 2006; 6: 2348–2355.

Neumann U, Puhl G, Bahra M, Berg T, Langrehr JM, Neuhaus R et al. Treatment of patients with recurrent hepatitis C after liver transplantation with peginterferon alfa-2B plus ribavirin. Transplantation. 2006; 82: 43–47.

Picciotto FP, Tritto G, Lanza AG, Addario L, De Luca M, Di Costanzo GG et al. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol. 2007; 46: 459–465.

Angelico M, Petrolati A, Lionetti R, Lenci I, Burra P, Donato MF et al. A randomized study on peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C. J Hepatol. 2007; 46: 1009–1017.

Carrion JA, Navasa M, Garcia-Retortillo M, Garcia-Pagan JC, Crespo G, Bruguera M et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology. 2007; 132: 1746–1756.

Sharma P, Marrero JA, Fontana RJ, Greenson JK, Conjeevaram H, Su GL et al. Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence. Liver Transplant. 2007; 13: 1100–1108.

Zimmermann T, Bocher WO, Biesterfeld S, Zimmermann A, Kanzler S, Greif-Higer G et al. Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation. Transplant Int. 2007; 20: 583–590.

Castells L, Vargas V, Allende H et al. Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. J Hepatol. 2005; 43 (1): 53–59.

Toniutto P, Fabris C, Fumo E et al. Pegylated versus standard interferon-α in antiviral regimens for posttransplant recurrent hepatitis C: comparison of tolerability and efficacy. Journal of Gastroenterology and Hepatology. 2005; 20 (4): 577–582.

Lodato F, Berardi S, Gramenzi A et al. Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation. Alimentary Pharmacology and Therapeutics. 2008; 28 (4): 450–457.

Хубутия МШ, Сюткин ВЕ, Салиенко АА, Карандашова ИВ, Долгин ВА, Чуланов ВП и др. Лечение гепатита С у реципиентов печени в Московском центре трансплантации печени в течение 10 лет. Трансплантология. 2013; 2: 5–13. Hubutija MSh, Sjutkin VE, Salienko AA, Karandashova IV, Dolgin VA, Chulanov VP i dr. Lechenie gepatita С u recipientov pecheni v Moskovskom centre transplantacii pecheni v techenie 10 let. Transplantologija. 2013; 2: 5–13. [In Russ, English abstract].

Эсауленко ЕВ, Сухорук АА. Обоснование использования безинтерфероновых терапевтических схем при хроническом гепатите С после трансплантации печени. Материалы VI Всероссийской научно-практической конференции «Инфекционные болезни как междисциплинарная проблема – вчера, сегодня, завтра» 26–27 октября 2015 года. Под общ. ред. акад. РАН В.И. Покровского. МО, Ногинск: АНАЛИТИКА РОДИС, 2015: 86–90. Еsaulenko EV, Sukhoruk AA. Obosnovanie ispol’zovanija bezinterferonovyh terapevticheskih shem pri hronicheskom gepatite C posle transplantacii pecheni. Materialy VI Vserossijskoj nauchno-prakticheskoj konferencii «Infekcionnye bolezni kak mezhdisciplinarnaja problema – vchera, segodnja, zavtra» 26–27 oktjabrja 2015 goda. Pod obshh. red. akad. RAN V.I. Pokrovskogo. MO, Noginsk: ANALITIKA RODIS, 2015: 86–90. [In Russ].

Сухорук АА, Эсауленко ЕВ, Яковлев АА, Хомченко ИВ. Эффективность противовирусной терапии рецидива хронического гепатита С у пациентов, перенесших трансплантацию печени. Журнал инфектологии. 2013; 5 (3): 35–39. Sukhoruk AA, Esaulenko EV, Jakovlev AA, Homchenko IV. Jeffektivnost’ protivovirusnoj terapii recidiva hronicheskogo gepatita C u pacientov, perenesshih transplantaciju pecheni. Zhurnal infektologii. 2013; 5 (3): 35–39. [In Russ, English abstract].

Coilly A, Roche B, Dumortier J, Leroy V, Botta-Fridlund D, Radenne S et al. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. J Hepatol. 2014; 60: 78–86.

Pungpapong S, Aqel BA, Koning L, Murphy JL, Henry TM, Ryland KL et al. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation. Liver Transpl. 2013; 19: 690–700.

Werner CR, Egetemeyr DP, Lauer UM, Nadalin S, Königsrainer A, Malek NP et al. Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: a 12-week pilot study providing safety and efficacy data. Liver Transpl. 2012; 18: 1464–1470.

Ann Brown K, Russo M, Levitsky J, Yoshida E, Vargas H, Bsharat M et al. Twice – daily Telaprevir in combination with Peginterferon alfa 2α/ribavirin in genotype 1 HCV Liver Transplant recipients: Interim week 16 Safety and Efficacy Results on the Prospective, Multicenter REFRESH Study. Hepatology. 2013; 58: 4.

Faisal N, Yoshida EM, Bilodeau M, Wong P, Ma M, Burak KW et al. Protease inhibitor-based triple therapy is highly effective for hepatitis C recurrence after liver transplant: a multicenter experience. Ann Hepatol. 2014; 13: 525–532.

Werner CR, Egetemeyr DP, Nadalin S, Königsrainer A, Malek NP, Lauer UM et al. Treatment of recurrent genotype 1 hepatitis C post-liver transplantation: single center experience with telaprevir-based triple therapy. Gastroenterol. 2014; 52: 27–34

Garg V, van HR, Lee JE, Alves K, Nadkarni P, Luo X. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology. 2011; 54: 20–27.

Charlton M. Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents – a potentially lethal cocktail. Hepatology. 2011; 54: 3–5.

Ikegami T, Yoshizumi T, Yoshida Y, Kurihara T, Harimoto N, Itoh S et al. Telaprevir versus simeprevir for the treatment of recurrent hepatitis C after living donor liver transplantation. Hepatol Res. 2015 Jun 19. doi: 10.1111/ hepr.12546. [Epub ahead of print]. Available from: http:// www.ncbi.nlm.nih.gov./pubmed/26096514#.

Kwo PY, Mantry PS, Coakley E, Te HS, Vargas HE, Brown RJr et al. An Interferon-free Antiviral Regimen for HCV after Liver Transplantation. N Engl J Med. 2014; 371: 2375–2382.

Price JC, Terrault NA. Treatment of Hepatitis C in Liver Transplant Patients: Interferon OUT, Direct Antiviral Combos IN. Liver Transpl. 2015; 21 (4): 423–434.

Gilead Sciences. Safety and Efficacy of Sofosbuvir and Ribavirin in Adults With Recurrent Chronic Hepatitis C Virus (HCV) Post Liver Transplant (NCT01687270) December 2014. Available from: https://clinicaltrials.gov/ ct2/show/NCT01687270?term=NCT01687270& rank=1.

Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown JrRS et al. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients with Advanced Liver Disease. Gastroenterology. 2015; 149: 649–659.

Reddy KR, Everson G, Flamm S, Denning J, Arterburn S, Brandt-Sarif T et al. Ledipasvir/sofosbuvir with ribavirin for the treatment of HCD in patients with post-transplant recurrence: preliminary results of a prospective multicenter study. Abstract # 8. Hepatology. 2014; 60: 200A.

Poordad F, Schiff ER, Vierling JM, Landis C, Fontana RJ, Yang R et al. Daclatasvir, Sofosbuvir and Ribavirin combination for HCV patients with advanced cirrhosis or posttransplant recurrence: Phase 3 ALLY-1 Study. 50th EASL; Vienna, Austria; April 22–26, 2015. Abst. LO8.

Janssen Scientific Affairs. An Efficacy and Safety Study of Simeprevir and Sofosbuvir With and Without Ribavirin in Participants With Recurrent Genotype 1 Hepatitis C Post-Orthotopic Liver Transplant (GALAXY) (NCT02165189) January 2016. Available from: https:// clinicaltrials.gov/ct2/show/NCT02165189?term=An+Ef ficacy+and+Safety+Study+of+Simeprevir+and+Sofosb uvir&rank=1.

Pungpapong S, Aqel B, Leise M et al. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant. Hepatology. 2015; 61: 1880–1886.

Gutierrez JA, Carrion AF, Avalos D, O’Brien C, Martin P, Bhamidimarri KR et al. Sofosbuvir and Simeprevir for Treatment of Hepatitis C Virus Infection in Liver Transplant Recipients. Liver Transpl. 2015; 21 (6): 823– 830.

Brown RSJr, O’Leary JG, Reddy KR, Kuo A, Morelli GJ, Burton JRJr et al. Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: Real-world experience from the hepatitis C therapeutic registry and research network. Liver Transplantation. 2016; 22 (1): 24–33.

Nguyen NH, Yee BE, Chang C, Jin M., Lutchman G, Lim JK et al. Nguyen Tolerability and effectiveness of sofosbuvir and simeprevir in the post-transplant setting: systematic review and metaanalysis. BMJ Open Gastro. 2015; 2: e000066.

Инструкция по применению лекарственного препарата для медицинского применения Сунвепра. Available from: http://grls.rosminzdrav.ru/ Grls_View_ v2.aspx? idReg=374742&t= Instrukcija po primeneniju lekarstvennogo preparata dlja medicinskogo primenenija Sunvepra. Available from: http://grls.rosminzdrav.ru/ Grls_View_v2.aspx? idReg=374742&t=[In Russ].

Dick TB, Lindberg LS, Ramirez DD, Charlton MR. A clinician’s guide to drug-drug interactions with directacting antiviral agents for the treatment of hepatitis C viral infection. Hepatology. 2016; 63: 634–643.

The authors declare that there are no conflicts of interest present.